KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Long-Term Debt Repayments: 2019-2025

Historic Long-Term Debt Repayments for BeOne Medicines (ONC) over the last 3 years, with Sep 2025 value amounting to $4.3 million.

  • BeOne Medicines' Long-Term Debt Repayments rose 19.71% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.5 million, marking a year-over-year increase of 38.16%. This contributed to the annual value of $28.0 million for FY2024, which is 104.76% up from last year.
  • BeOne Medicines' Long-Term Debt Repayments amounted to $4.3 million in Q3 2025, which was down 66.12% from $12.6 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Long-Term Debt Repayments ranged from a high of $12.6 million in Q2 2025 and a low of -$1.5 million during Q2 2023.
  • In the last 3 years, BeOne Medicines' Long-Term Debt Repayments had a median value of $4.3 million in 2025 and averaged $5.7 million.
  • The largest annual percentage gain for BeOne Medicines' Long-Term Debt Repayments in the last 5 years was 816.61% (2024), contrasted with its biggest fall of 57.92% (2024).
  • Quarterly analysis of 3 years shows BeOne Medicines' Long-Term Debt Repayments stood at $5.2 million in 2023, then surged by 99.89% to $10.4 million in 2024, then increased by 19.71% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $12.6 million for Q2 2025, and $4.2 million during Q1 2025.